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Studying the distribution of deep Raman
spectroscopy signals using liquid tissue phantoms
with varying optical properties
Martha Z. Vardaki,a Benjamin Gardner,a Nicholas Stone*†a and Pavel Matousek*†b
In this study we employed large volume liquid tissue phantoms, consisting of a scattering agent (Intra-
lipid), an absorption agent (Indian ink) and a synthesized calciﬁcation powder (calcium hydroxyapatite
(HAP)) similar to that found in cancerous tissues (e.g. breast and prostate), to simulate human tissues. We
studied experimentally the magnitude and origin of Raman signals in a transmission Raman geometry as a
function of optical properties of the medium and the location of calciﬁcations within the phantom. The
goal was to inform the development of future noninvasive cancer screening applications in vivo. The
results provide insight into light propagation and Raman scattering distribution in deep Raman measure-
ments, exploring also the eﬀect of the variation of relative absorbance of laser and Raman photons within
the phantoms. Most notably when modeling breast and prostate tissues it follows that maximum signals is
obtained from the front and back faces of the tissue with the central region contributing less to the
measured spectrum.
Introduction
Deep Raman spectroscopy consists of a group of emerging
spectroscopic techniques being developed for biomedical,
pharmaceutical and security applications based around
Spatially Oﬀset Raman Spectroscopy (SORS and Transmission
Raman Spectroscopy (TRS)).1,2 In contrast to conventional
Raman spectroscopy, deep Raman has been shown to be able
to acquire specific molecular signals from calcifications from
depths up to 2.7 cm,3 or 5 cm with the use of labelled nano-
particles (SESORS).4 The feasibility of non-labelled deep
Raman approaches has been already demonstrated for poten-
tial application to breast cancer3 and bone disease5,6 diagnos-
tics. A further demonstration of the potential for clinical SORS
has been shown in a feasibility study to assess the surgical
margins in excised breast tumour samples.7 Transmission
mode has also been used for signal recovery in various studies,
with examples of Raman and diﬀuse optical tomography on
bone8 and breast9 tissue phantoms.
However, in the studies above, the measured Raman scatter-
ing has only been explored in terms of signal intensity versus
tissue thickness. A major unexplored aspect of deep Raman is
the spatial distribution of the Raman scattering throughout a
sample volume and its dependence on optical properties of
the sample.
Related research has been conducted on pharmaceutical
tablets, studying the spatial origin of measured Raman signals
changes when both in spatial and time-resolved transmission
Raman measurements5,10 and in respective Monte Carlo simu-
lations.11 However, because of the great diﬀerence between bio-
logical tissue and pharmaceutical formulations (e.g. presence of
absorption in tissue, diﬀerent spatial scales), the medical appli-
cations warrant a specific and tissue-oriented study.
In the field of Raman fiberoptic probes, a needle fibre optic
probe has been developed and tested for subcutaneous Raman
measurements by being inserted beneath the surface of
various ex vivo biological tissues to acquire a Raman signal.12
Even though Raman needle probes can enable significant
depth probing, they are invasive and generally only sample a
volume restricted to a zone local to the probe tip.
For the first time, our measurements explore experimentally
the signal distributions in tissue phantoms representing pros-
tate and breast tissue. To ensure that our measurements are
comparable to real conditions, we produced liquid tissue phan-
toms with optical properties comparable to these types of tissue.
Prostate cancer is nowadays the third most common male
cancer in UK with more than 30 000 new cases every year.
Some of the most common tests taken to detect prostate
cancer (PSA, digital rectal exam, ultrasound) are not always
reliable since they can only detect the gross morphological† Joint senior authors.
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changes on the gland and often fail to determine if these
changes are due to a cancerous condition.13–15 As a result,
more invasive methods such as prostate biopsy and histo-
pathology are being applied for the definite diagnosis and
classification of the disease. However, if the tumor is small, it
can be missed by biopsy since only a very small percentage of
the entire gland is sampled.16
Breast cancer is also one of the most common cancer types
with over 50 000 women diagnosed every year in UK. With
mammography being vastly aﬀected by breast tissue
density17,18 and ultrasound exhibiting a low sensitivity,19
current diagnostic means seem to be insuﬃcient for an ade-
quate early diagnosis. The gold standard for breast cancer is
currently biopsy followed by histopathology. However, even in
that case not all of the tissue can be sampled in order to be
assessed as cancerous or benign.20
Conventional Raman spectroscopy has already established
the feasibility of detecting prostate and breast cancer ex vivo.
Studies have shown the possibility of distinguishing between
normal prostate, benign prostatic hyperplasia and diﬀerent
grades of prostatic carcinoma.21,22 In the case of breast cancer,
a number of studies have also managed to discriminate
between healthy, benign and malignant breast tissue using
Raman spectroscopy under the microscope.23
Deep Raman techniques have also shown potential in dis-
tinguishing between benign and malignant breast tissue, on
the grounds of the detection of diﬀerent types of calcifications
which appear in diﬀerent pathological types of breast
tissue.3,24 Therefore, it is clear that methods able to probe
Raman signals from the tissue volume of interest such as
spatially oﬀset Raman spectroscopy (SORS) or transmission
Raman spectroscopy, have the potential to provide a minimally
invasive solution for in vivo diagnosis of the disease.
This study has explored the feasibility of acquiring Raman
signals from each point across a two-dimensional grid in the
tissue phantom. The objectives have been to enable both an
understanding of the relative signals measured from lesions
buried at diﬀerent depths in tissues and to help the future
design of optical sampling methods to maximise the excitation
and collection of these signals. In order to explore how the
photon migration of the Raman signals change when the
optical properties of the surrounding tissue change, we pro-
duced a selection of liquid tissue phantoms within a 30 mm ×
45 mm × 45 mm quartz cell. In this way we simulated the
potential in vivo measurement conditions for human prostate
(transurethrally and transrectally) and breast samples and
assessed the feasibility of such measurements.
Results and discussion
Intralipid maps
Raman scattering maps were recorded for tissue phantoms
with diﬀerent Intralipid (IL) concentrations and therefore
diﬀerent scattering coeﬃcients (Fig. 1). Parameters such as
Fig. 1 The origin of Raman signal in diﬀerent Intralipid concentration
tissue phantoms when no absorber is present. Laser photons are
injected on the left of the image and Raman signal is collected on the
right. A cuvette of the calcium hydroxyapatite (HAP), 12 mm width ×
4 mm (2 mm optical path length), has been moved in steps of 1 and
2 mm across a two-dimensional grid. The 12 mm cuvette width is
aligned with y-axis in the images and the 4 mm path aligned with the
optical axis of the model system (x-axis in the ﬁgure). The HAP cuvette
was kept immersed in the phantom at all times. The plots depict the
intensity of ∼960 cm−1 phosphate Raman band of HAP. The right-hand
plots represent longitudinal plots of generated Raman signal along the
optical axis (‘on axis’ Raman intensity).
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power, laser wavelength, beam size and acquisition time were
kept constant during the mapping.
In the plain water mapping (Fig. 1a) no diﬀuse scattering is
present and the measured signal is limited to the boundaries
of the laser beam. Once we introduce Intralipid into the
system (Fig. 1b), laser photons are able to reach and interact
with HAP in more distant oﬀ axis positions as they elastically
scatter between suspended lipid droplets. Therefore, Raman
signal can be detected outside of the boundaries of the illumi-
nating beam with limits that depend on the scatterer (Intra-
lipid) concentration in the tissue phantom.
As the numbers of Intralipid molecules in the phantom
increase (moving from Fig. 1a–g), the scattering distribution
pattern changes. In phantoms with low scattering coeﬃcients
(Fig. 1b) we observe a form of symmetry in the Raman signal
between the illumination (left) and the collection (right) side.
It should be considered here that the highest number of
Raman photons are expected to be generated on the illumina-
tion side because this is where most of the laser photons are
present in the cell, with the greatest probability of inducing
Raman events. However, these photons need to propagate
across the entire width of the cell through the turbid medium
to the right side in order to be detected; undergoing loss due
to scattering and absorption. On the other hand, when the
sample cuvette is on the collection side of the phantom, the
Raman photons generated there are more eﬃciently collected,
since this is where they have the least distance to travel in
order to reach and be detected by the collection optics.
The distribution of Raman scattering signals across the
maps will always be a balance between these two phenomena.
As Intralipid molecules in the tissue phantom increase in con-
centration (Fig. 1c and d), it is progressively less likely for the
Raman photons generated at the illumination spot to pass
through the phantom volume and be detected on the other
side of the cell prior to being absorbed or scattered out of the
sample (signal balance moves to the collection (right) side).
As Intralipid concentration rises further (Fig. 1e–g), the
path lengths for both laser and Raman photons increase con-
siderably and therefore the water absorption engenders more
significant impact on the signal distribution pattern. As men-
tioned in the literature25 and also confirmed with our
measurements (Fig. 2), water absorbs the Raman photons gen-
erated in our setup (at 902 nm) more than the laser photons
(830 nm). This explains why the signal balance moves to the
collection surface (right), as it is easier for laser photons to tra-
verse diﬀusely the cell than Raman photons, when the scatter-
ing increases.
Another important feature evidenced by the maps is that
the higher the Intralipid concentration is, the broader the
measurable signal region becomes. This means that a lesion
located oﬀ the illumination–collection axis would be more
likely to be detected in tissues with higher turbidity (modelled
with higher Intralipid concentrations) than a lower one. This
becomes clear if we compare maps with low Intralipid concen-
trations (Fig. 1b and c) with the ones with increased Intralipid
(Fig. 1d–g).
The maps above support our understanding of Raman scat-
tering distribution throughout the phantom volume, in the
absence of any additional absorber apart from water itself. In
the next step, we explored how this distribution changes under
the influence of both scattering and elevated absorption,
which is the case of real tissue.
Intralipid and India ink maps
Intralipid and Indian ink were combined in liquid tissue phan-
toms to best simulate real human breast and prostate tissue
optical properties. In the first set of experiments a cuvette of
HAP (calcium hydroxyapatite, a type of calcification found in
tissues) was used to explore the eﬀect of varying the optical
properties on the recovery of signals from various locations
within the phantom volume (Fig. 3).
In these maps, when scattering and absorption agents are
both present at low concentrations (Fig. 3a), we observe a
strong Raman signal from both the illumination and the col-
lection sides. If we double the density of scatterer but maintain
the absorber concentration constant (Fig. 3b), the signal on
the collection side is being significantly suppressed. This is
due to the significant increase in the photon path length
which directly increases the chances of the laser and Raman
photons being absorbed by the Indian ink. For the same
reason, when we increase the ink concentration, we expect a
similar eﬀect on the mapping pattern (Fig. 3c) where IL con-
centration was kept constant as in (a) but the concentration of
the ink was increased.
Indian ink aqueous solution has been shown through UV/Vis
absorbance measurements (Fig. 4) to absorb the laser photons
(830 nm) more than the generated Raman ones (902 nm), i.e.
the opposite net eﬀect to that induced by water alone.
Consequently, the detected signal is much less likely to
originate from the collection side of the phantom, as there are
relatively less laser photons reaching it.
Fig. 2 Absorbance spectra of water in the range of 400–1100 nm.
Negative absorbance values are due to the diﬀerence in refractive index
between air (used as a blank in the cuvette) and water. The cuvette path
length in the measurements is 1 mm.
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To characterise the system at the maximum range of pros-
tate tissue relevant absorption and scattering conditions,
which are higher than those used earlier in the paper, we had
to resort to a stronger Raman scatterer, trans-stilbene. By repla-
cing HAP with trans-stilbene it was possible to probe higher
IL/ink concentration solutions with the existing Raman appar-
atus and while recording trans-stilbene’s peak at 1192 cm−1
(921 nm). With this sample, we could still observe the same
distribution pattern with the two maxima on illumination and
collection side.
However, when we increase the absorption further (Fig. 5b),
the collection side becomes more dominant. We should
mention here that the absorption coeﬃcient in Fig. 5b is well
above the absorption range of human prostate and breast
tissue and was only tested to assess the detection limits of our
system. Additionally, with this level of absorber present, the
Raman signal measured was of the order of the noise, which
makes the data processing prone to errors.
The findings from this study enable us to design optimised
instrumentation for use with tissue samples. We expect that
appropriate modifications in our system (increased laser
power, minimized loss of laser photons from the sample using
a ‘photon diode’, improved collection eﬃciency and opening
slits and using high dispersion gratings) will increase signals
by around two orders of magnitude; enabling the probing of
samples with weaker signals at these depths.
Experimental
Tissue phantom optical properties
Inclusion-containing tissue phantoms with specific optical
properties are a common approach to simulate tissues in deep
Raman techniques.8,26,27 Intralipid (Fresenius Kabi Ltd,
Fig. 4 Absorbance spectra of diﬀerent Indian ink aqueous solutions
concentrations (in microliters per ml) in the range of 400–1100 nm. The
cuvette path length in the measurements is 1 cm.
Fig. 5 Raman scattering 2D(i) and 1D(ii) plots of diﬀerent Intralipid/ink
concentration trans-stilbene tissue phantoms.
Fig. 3 Raman scattering 2D(i) and 1D(ii) plots of diﬀerent Intralipid/ink
concentration HAP tissue phantoms.
Paper Analyst



































United Kingdom) and Indian ink (Histology Stain, American
MasterTech) were used to induce diﬀuse scattering and absor-
bance in tissue phantoms respectively. Intralipid, a dilute
mixture of emulsified fatty acids serves as a scattering medium
whereas Indian ink, a dispersion of carbon particles, acts as a
broad band absorbing agent.
The Indian ink and Intralipid concentrations in phantoms
were determined to match those for human prostate and
breast tissue optical properties of absorbance and scattering,
as found in the literature. However, there is only limited data
in the literature on tissue optical properties for the laser wave-
length of 830 nm.
The reduced scattering (μ′s) and absorption (μa) coeﬃcient
values, for normal and cancerous prostate glands, have been
calculated through optical extinction and diﬀusion reflectance
measurements. The values calculated for μ′s at 830 nm
were 4 cm−1 for healthy and 6 cm−1 for cancerous prostate
glands, whereas the values for μ′a were estimated to be
0.027 cm−1 for healthy and 0.002 cm−1 for cancerous prostate
respectively.28
Svensson et al. used NIR time-resolved spectroscopy to esti-
mate the reduced scattering coeﬃcient between 5.5 and
9.5 cm−1 and absorption coeﬃcient between 0.3 and 0.7 cm−1
for malignant prostate glands with untreated cancer.29
Concerning breast tissue, the reduced scattering coeﬃcient
has been calculated for 830 nm wavelength to be μ′s =
9.84 cm−1.30 Breast tissue absorption coeﬃcients are not avail-
able in the literature for the exact wavelength of 830 nm, but a
value of μa between 0.068 and 0.102 cm−1 in papillary breast
cancer is estimated for the very close wavelength of
825 nm.30,31
Based on the literature values for reduced scattering and
absorption coeﬃcients of human prostate and breast tissues,
we built liquid tissue phantoms using Intralipid and Indian
ink concentrations which would provide equivalent values of
optical properties.
Intralipid has been well characterized in terms of optical
properties in the literature. Using the fitting parameters for
10%, 20% and 30% Intralipid provided by Michels et al.32 for
calculating the Intralipid optical properties and converting for
our wavelength, we plotted a fit line through which we
extracted the Intralipid concentrations equivalent to the
required reduced scattering coeﬃcient values (Fig. 6).
Using these values, liquid tissue phantoms with reduced
scattering coeﬃcients of: 2.3, 4.6, 9.2, 18.4, 27.7 and 36.9 cm−1
were produced, using Intralipid concentrations calculated
based on the calibration line expression (y = 92.179x).
In terms of absorption properties, diﬀerent concentrations
of Indian ink were used to achieve diﬀerent absorption coeﬃ-
cients in the phantom. Indian ink from diﬀerent manufac-
turers has been widely employed and characterized in various
studies.33 In this study we measured the absorption coeﬃcient
of our specific sample of Indian ink.
After having recorded UV/Vis absorption spectra of diﬀerent
ink concentrations, our data were curve fitted for the appropri-
ate wavelength (830 nm) and the ink concentrations required
for the human tissue absorption change were calculated.34 Our
data were in a very good agreement with the literature, at least
in the concentrations mentioned.28 Liquid phantoms were pro-
duced with absorption coeﬃcients of: 0.37, 0.80 and
2.26 cm−1.
To simulate the optical properties of prostate and breast
tissues, the scattering and absorption agents were combined
in the same sample. The liquid tissue phantoms which were
made to cover the range of optical properties in human pros-
tate and breast tissues, are summarized in the Table 1.
Tissue phantom preparation
The liquid phantoms consisted of a quartz cell (45 mm width
× 30 mm length (26 mm internal cell optical path length) ×
45 mm height) (ramé-hart instrument co., USA) containing
aqueous solutions of Intralipid and Indian ink in various
concentrations.
A thin cuvette (12 mm width, 4 mm length (2 mm optical
path length)) containing hydroxyapatite (HAP) or trans-stil-
Fig. 6 Percentage Intralipid concentration versus reduced scattering
coeﬃcient (cm−1).
Table 1 Optical properties of the simple (only Intralipid) and combined
(Intralipid and Indian ink) liquid tissue phantoms constructed in relation
to the human prostate tissue range. The right hand column shows the
material used to provide the Raman signal in each of the phantoms
μ′s (cm−1) μa (cm−1) Raman signal
Phantom a 0 — HAP
Phantom b 2.3 — HAP
Phantom c 4.6 — HAP
Phantom d 9.2 — HAP
Phantom e 18.4 — HAP
Phantom f 27.7 — HAP
Phantom g 36.9 — HAP
Phantom 1 4.6 0.37 HAP
Phantom 2 9.2 0.37 HAP
Phantom 3 4.6 0.80 HAP
Phantom 4 9.2 0.80 trans-Stilbene
Phantom 5 9.2 2.26 trans-Stilbene
Prostate tissue 4–9.5 0.002–0.7 —
Breast tissue 9.84 0.068–0.102 —
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bene, was placed inside the quartz cell (see Fig. 7). The cuvette
width (12 mm) was aligned with the y-axis and the 4 mm path
is aligned with the optical axis of the system (x-axis). The cuvette
was also attached to a motorized translation stage (Standa Ltd,
Lithuania) and moved to 300 diﬀerent positions in a two-dimen-
sional grid inside the quartz cell during each mapping.
It should be mentioned here that the large quartz cell
dimensions were chosen in order to provide a first approxi-
mation to both breast volumes in mammographic screening
(1.9–7.2 cm compressed breast thickness)35 and human pros-
tate gland dimensions (4–4.5 cm length, 2–3.5 cm width,
1.7–2.5 cm thickness),36 so that the phantoms are able to
approximate both in size and optical properties.
HAP was selected for these experiments to represent patho-
biological material that is found in both breast and prostate
tissues. Most importantly here, it has a distinct signal from
surrounding soft tissues (or Intralipid here) and therefore the
signals could be clearly identified. Calcifications already
exhibit a crucial feature in various types of cancer such as
breast cancer37 and prostate cancer.38 The HAP cuvette used in
our experiments has a similar composition to that found in
cancerous calcifications of the breast.39
Two diﬀerent groups of liquid phantoms have been
utilised.
(a) Scatterer only phantoms: cell containing an aqueous
solution of Intralipid in diﬀerent concentrations, ranging from
0–4%.
(b) Tissue representing phantoms: cell containing an
aqueous solution of Intralipid and Indian ink in concen-
trations ranging from 0.5–1% for the first and 0.1–0.5 μl ml−1
for the second.
In the first place, liquid tissue phantoms containing HAP
were employed to run a range of absorber and scatterer con-
centrations. Secondly, trans-stilbene was used to explore the
system when the detection limits with HAP were reached,
when using the higher scatterer and absorber concentrations
in the samples.
Indian ink phantoms in diﬀerent concentrations with no
Intralipid, have also been used, in order to assess the indivi-
dual eﬀect of ink on light propagation in the samples (not
shown here for brevity). Whenever Indian ink was used, it was
first subjected to ultrasound in an ultrasonic water bath for
30 minutes. This is necessary in order to prevent suspended
carbon particles from forming clusters in the aqueous solution
and maintain reproducible ink optical properties.40,41
Deep Raman setup
The deep Raman system at Exeter University used a trans-
mission Raman configuration (Fig. 8). It consisted of a spec-
trum stabilized laser (Innovative Photonics Solutions) with
laser emission at 830 nm and an output power of ∼300 mW.
The laser was coupled to a Thorlabs 400 μm multimode patch
cord, collimated and filtered by passing through a pair of laser
line filters (FL830-10, Thorlabs) in order to suppress the oﬀ-
centre spectral emission from the laser line. The laser was
directed towards the sample with a mirror and brought onto
the sample with a 25 mm diameter, 70 mm focal length lens.
The sample was illuminated with 280 mW of light in a
3–4 mm diameter spot. The collimated light passing through
the tissue phantom is either scattered or absorbed by the
molecules present. The Raman scattered photons were col-
lected using an AR coated lens ( f = 60 mm, dia. = 50 mm,
INGCRYS Laser systems). The collimated scattered light was
passed through a holographic super notch filter (HSPF-830.0
AR-2.0, Kaiser Optical Systems) to remove the elastically scat-
tered light (laser photons) and imaged onto a fibre probe
bundle by a second lens of the identical parameters to the col-
lection lens (i.e. with no magnification). The fibre bundle
(CeramOptec, ‘spot to slit line’ type bundle assembly, active
area spot diameter approximately 2.21 mm, slit line approxi-
mately 0.25 mm × 14.95 mm) was connected to the entrance
port of a Holospec VPH system spectrograph (Kaiser Optical
systems Inc, HSG-917.4 custom). Maps were recorded using a
deep depletion CCD camera cooled down to −75 °C (Andor
Technology, DU420A-BR-DD, 1024 × 255 pixels). The overall
spectral resolution of the detection system was ∼8 cm−1.
The signal was collected using 6 accumulations of
5 seconds (apart from the water mapping where we recorded
the signal for 120 × 0.25 seconds to stay below the CCD satur-
ation levels) and the cosmic ray removal option of the detector
software (Andor Solis) was applied. The system was calibrated
using Raman bands of an aspirin tablet (acetylsalicylic acid).
Raman mapping
In order to explore the eﬀect of Raman scattering and light dis-
tribution in the diﬀerent tissue phantoms, the Raman spectra
of the tissue phantom when the cuvette was in 300 diﬀerent
positions (in the x–y plane) were recorded. The movements
were realized in ‘snake’ mode with the support of a motorized
x–y translation stage. To make most eﬃcient use of experi-
mental time, steps were 1 mm in the main beam area
(between 10–20 mm on x axis and 8–14 mm on y axis) and
Fig. 8 Diagram of the deep Raman setup in a transmission mode used.
Fig. 7 (i) Liquid tissue phantoms components. (ii) The quartz cell and
the HAP cuvette which were used in our measurements.
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2 mm around the edges of the large cell (the rest of the
mapping area). At each step, a Raman spectrum was recorded
and the stage was moved to the next position.
Data analysis
All data were loaded into Matlab R2013a (MathWorks), where
they were subjected to cosmic ray removal, baseline correction,
principal component (PC) noise reduction and subsequent
reconstruction from the first seven principal components
into 1D and 2D images for better signal distribution
visualization.
In these presented maps, the colour of the pixel indicates
the intensity above the fit baseline of the characteristic HAP
peak (959 cm−1) or in the case of stilbene the peak at
1192 cm−1.
Conclusions
In this study we explored the Raman scattering distribution in
the liquid tissue phantoms that mimic prostate and breast
tissues in both approximate size and optical properties of the
phantom. It has been clearly shown how the distribution of
the collected Raman scattering signals changes under
diﬀerent values of absorption and scattering coeﬃcients of the
phantom. The results elucidate the distribution of Raman
signals obtained from such extended tissue phantoms and
demonstrate that the highest signals are likely to be obtained
from nearer surface lesions than those at depth using trans-
mission Raman. Even in this case though, we have demon-
strated relative signals of around 40–60% for ‘lesions’ found in
the centre of organs compared to those found towards the
edges. This is contrary to observations reported earlier with
pharmaceutical tablets where layered samples (of extended/
infinite lateral dimensions) were investigated with minimal
contributions from absorbers. These studies demonstrated a
maximum signal originating from the centre of pharma-
ceutical tablets.10,11,42
This study shows promise for future applications of trans-
mission Raman, either in the breast or applied through fibre
probes, to the prostate. It has advanced the understanding of
how the distribution of collected Raman scattering signals
change in relation to a range of expected optical properties of
tissues. This helps the future design of instruments that we
may wish to use to target disease specific signals within par-
ticular regions of the sample and pave the way towards the ulti-
mate application of non-invasive deep Raman diagnosis of
prostate and breast cancer.
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